PATENT CLAIM ANALYSIS

Application Number: 16385062
Application Type: Utility
Filing Date: 2019-04
Publication Date: 2019-08
Patent Classification: ["424", "207100"]

Abstract:
Methods for inducing an immune response against Human Immunodeficiency Virus (HIV) in HIV-infected subjects undergoing antiretroviral therapy (ART) are described. The methods include administering an adenovirus vector primer vaccine and a modified vaccinia virus (MVA) vector booster vaccine encoding mosaic HIV antigens.

Claim (Index 12):
A method of inducing an immune response against a human immunodeficiency virus (HIV) in an HIV-infected human subject undergoing antiretroviral therapy (ART), the method comprising:\n (i) administering to the human subject a primer vaccine comprising an immunogenically effective amount of a first adenovirus 26 (Ad26) vector encoding a mosaic HIV antigen of SEQ ID NO: 1, a second Ad26 vector encoding a mosaic HIV antigen of SEQ ID NO: 3, and a third Ad26 vector encoding a mosaic HIV antigen of SEQ ID NO: 4, and a pharmaceutically acceptable carrier; and (ii) administering to the human subject a booster vaccine comprising an immunogenically effective amount of a first modified vaccinia ankara (MVA) vector encoding mosaic HIV antigens of SEQ ID NOs: 1 and 3, and a second MVA vector encoding mosaic HIV antigens of SEQ ID NOs: 2 and 4, and a pharmaceutically acceptable carrier, wherein the first and second MVA vectors, wherein the primer vaccine is re-administered at about 10-14 weeks after the primer vaccine is initially administered; the booster vaccine is first administered at about 22-26 weeks after the primer vaccine is initially administered; and the booster vaccine is re-administered at about 46-50 weeks after primer vaccine is initially administered; and wherein the human subject initiated ART during acute HIV infection and the human subject has sustained viremic control defined as plasma HIV RNA of less than 50 copies per ml for at least 48 weeks prior to the initial administration of the primer vaccine, optionally with one or more blips of plasma HIV RNA greater than 50 copies/ml to less than 20 copies/ml, provided that screening immediately prior to initial administration of the primer vaccine is less than 50 copies per ml.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 100.0
- Lexical Diversity: 1.21951
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15693650', '15968834', '14863808', '15380123', '14632433']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6972079380147238
- 35 USC 102 Novelty (BERT): 0.6782420382295121
- Combined Prediction Score: 0.6953113480362026
- Mean Citation Score: 488.40392
- Max Citation Score: 690.0668
- Similarity Product: 653.1199302470445

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test